Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011

Eur Urol Focus. 2022 Apr 18:S2405-4569(22)00078-5. doi: 10.1016/j.euf.2022.04.001. Online ahead of print.

ABSTRACT

Recent data from IMvigor010 impressively demonstrate the potential of circulating tumor DNA (ctDNA) as a prognostic and a predictive biomarker in patients with urothelial carcinoma. Although ctDNA status was prospectively assessed, the published data are only exploratory and require further prospective validation. Results from the IMvigor011 trial are therefore eagerly awaited.

PMID:35450799 | DOI:10.1016/j.euf.2022.04.001